Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C. Vencken PM, et al. Among authors: kriege m. Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29. Ann Oncol. 2013. PMID: 23543211 Free article.
Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
Zaaijer LH, van Doorn HC, Mourits MJ, van Beurden M, de Hullu JA, Adank MA, van Lonkhuijzen LR, Vasen HF, Slangen BF, Gaarenstroom KN, Zweemer RP, Vencken PM, Seynaeve C, Kriege M. Zaaijer LH, et al. Among authors: kriege m. Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18. Br J Cancer. 2016. PMID: 27755534 Free PMC article.
Survival and prognostic factors in BRCA1-associated breast cancer.
Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG. Brekelmans CT, et al. Among authors: kriege m. Ann Oncol. 2006 Mar;17(3):391-400. doi: 10.1093/annonc/mdj095. Epub 2005 Dec 1. Ann Oncol. 2006. PMID: 16322115 Free article.
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
Vencken PMLH, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C. Vencken PMLH, et al. Among authors: kriege m. Ann Oncol. 2011 Jun;22(6):1346-1352. doi: 10.1093/annonc/mdq628. Epub 2011 Jan 12. Ann Oncol. 2011. PMID: 21228333 Free article.
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N, van der Hout A, Oosterwijk JC, Vos JR; HEBON; Devilee P, van Engelen K, Meijers-Heijboer H, van der Luijt RB, Kriege M, Mensenkamp AR, Rookus MA, van Roozendaal KE, Mourits MJE, de Bock GH. Teixeira N, et al. Among authors: kriege m. Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26. Eur J Hum Genet. 2018. PMID: 29483665 Free PMC article.
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators; Collée JM, Couch FJ, Daly MB, Dennis J, Dhawan M, Domchek SM, Eeles R, Engel C, Evans DG, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Gayther SA, Gerdes AM, Godwin AK, Goldgar DE, Hahnen E, Hake CR, Hamann U, Hogervorst FBL, Hooning MJ, Hopper JL, Hulick PJ, Imyanitov EN; OCGN Investigators; HEBON Investigators; KconFab Investigators; Isaacs C, Izatt L, Jakubowska A, James PA, Janavicius R, Jensen UB, Jiao Y, John EM, Joseph V, Karlan BY, Kets CM, Konstantopoulou I, Kwong A, Legrand C, Leslie G, Lesueur F, Loud JT, Lubiński J, Manoukian S, McGuffog L, Miller A, Gomes DM, Montagna M, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Olah E, Olopade OI, Park SK, Parsons MT, Peterlongo P, Piedmonte M, Radice P, Rantala J, Rennert G, Risch HA, Schmutzler RK, Sharma P, Simard J, Singer CF, Stadler Z, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE… See abstract for full author list ➔ Lakeman IMM, et al. Genet Med. 2021 Sep;23(9):1726-1737. doi: 10.1038/s41436-021-01198-7. Epub 2021 Jun 10. Genet Med. 2021. PMID: 34113011 Free PMC article.
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG. Brekelmans CT, et al. Among authors: kriege m. Eur J Cancer. 2007 Mar;43(5):867-76. doi: 10.1016/j.ejca.2006.12.009. Epub 2007 Feb 20. Eur J Cancer. 2007. PMID: 17307353
90 results